Caisson Biotech, a leader in half-life extension and drug delivery, has established a global manufacturing partnership with CordenPharma, a full-service contract development and manufacturing organization (CDMO) manufacturing APIs and drug products through a network of cGMP facilities across Europe and the U.S.

Caisson has demonstrated successful technology transfer and cGMP scale-up with its corporate pharmaceutical partners utilizing its patented heparosan-based half-life extension and drug delivery platform, HEPtune, and will establish similar capabilities with CordenPharma in order to supply licensing partners with HEPtune drug conjugate material. As a manufacturer of the HEPtune technology, CordenPharma will bring experience and expertise in process development and manufacture of complex carbohydrates, including carbohydrate-based polymers and glyco-conjugates, which are an integral component of its peptides, lipids and carbohydrates technology platform offering.

“We are excited to announce a manufacturing relationship with CordenPharma,” said Breca Tracy, vice president and managing director, Caisson. “CordenPharma’s experience manufacturing carbohydrates and polyethylene glycol drug conjugates makes CordenPharma an ideal scale-up manufacturing partner and will accelerate Caisson’s capabilities to fulfill requests for larger quantities of quality material for pre-clinical and clinical studies.”

Mimoun Ayoub, director, global peptides, lipids, carbohydrates and injectables platforms, CordenPharma, said, “We are delighted that Caisson Biotech has selected CordenPharma to serve as a manufacturer and supplier of HEPtune-related materials. This potentially disruptive technology is a natural fit for CordenPharma’s peptides, lipids and carbohydrates platform, and we look forward to supporting Caisson Biotech’s partners as they develop and commercialize novel, life-saving therapeutics.”